Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;29(3):269-71.
doi: 10.1097/INF.0b013e3181c15977.

Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine

Alfonso Carmona  1 , Mariano Miranda, Francisco Barrio, Ana De Vicente, Josep Mares, Eulalia Muñoz, Javier Diez-Delgado, Angeles Alonso, Francisco Giménez-Sánchez, José Merino, Pilar García-Corbeira, Gudrun Maechler, Dominique Boutriau; Spanish 103954 Study Group
Collaborators, Affiliations

Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine

Alfonso Carmona et al. Pediatr Infect Dis J. 2010 Mar.

Abstract

A booster dose of Haemophilus influenzae type b-Neisseria meningitidis serogroup C conjugate (Hib-MenC-TT) vaccine simultaneously administered with measles, mumps, and rubella (MMR) vaccine in 13- to 14-month-old Spanish toddlers, primed with 3 doses of a combined Diphteria-Tetanus-Acellular Pertusis DTPa-Hib-containing vaccine and a MenC-CRM197 conjugate vaccine, had a good reactogenicity profile and induced similar Hib and MenC booster responses and MMR seropositivity rates as the vaccines given alone.

Trial registration: ClinicalTrials.gov NCT00263653.

PubMed Disclaimer

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources